![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 15, Issue 9, 4299-4309, September 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|| ¶* Departments of Dermatology, University of Michigan Medical Center, Ann Arbor, MI 48109; || Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109; and ¶ Ann Arbor Veterans Affairs Health System, Ann Arbor, MI 48105
Submitted March 18, 2004;
Revised July 2, 2004;
Accepted July 6, 2004
Monitoring Editor: Carl-Henrik Heldin
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
; Olayioye et al., 2000). Ligand binding to the extracellular domain promotes receptor homo- and heterodimerization, resulting in phosphorylation of specific tyrosine residues on the cytoplasmic domain. These events lead to activation of multiple signal transduction pathways via Src homology 2 (SH2)- and phosphotyrosine binding (PTB)-domain containing cytoplasmic proteins, ultimately affecting many cellular functions, including cell migration, proliferation, and differentiation (Hubbard et al., 1998; Hackel et al., 1999). We and others have demonstrated that human skin expresses ErbB1, ErbB2, and ErbB3, but little or no ErbB4 (Press et al., 1990; Prigent et al., 1992; De Potter et al., 2001; Stoll et al., 2001).
ErbB signaling plays a very important role in the reepithelialization of skin wounds, as evidenced by acceleration of burn or partial-thickness wound healing by epidermal growth factor (EGF) (Brown et al., 1989), transforming growth factor-
(TGF-) (Schultz et al., 1987), heparin-binding EGF-like growth factor (HB-EGF) (Cribbs et al., 1998), and epiregulin (Draper et al., 2003). Corneal wound healing also is markedly inhibited after treatment with ErbB receptor tyrosine kinase inhibitors (RTKIs) (Nakamura et al., 2001). Organ cultures of skin display many features of early wounds, including rapid keratinocyte cytoskeletal alterations, an early migratory phase without proliferation, and a later proliferative phase (Hebda, 1988; Varani et al., 1995b; Stoll et al., 2003). We have demonstrated marked inhibition of keratinocyte outgrowth and the induction of apoptosis by ErbB-specific RTKIs in human skin organ culture (Stoll et al., 1997, 1998).
Multiple ErbB ligands are expressed by keratinocytes, including TGF-, AR, HB-EGF, betacellulin, and epiregulin (Coffey et al., 1987; Barnard et al., 1994; Hashimoto et al., 1994; Piepkorn et al., 1998, 2003; Shirakata et al., 2000). Several of these ligands are up-regulated during wound healing (Grotendorst et al., 1989; McCarthy et al., 1996; Stoll et al., 1997), in hyperproliferative skin conditions such as psoriasis (Elder et al., 1989; Cook et al., 1992; Downing et al., 1997; Stoll and Elder, 1998) and retinoid-treated skin (Stoll and Elder, 1998; Varani et al., 2001), and during malignant transformation by chemical carcinogens (Kiguchi et al., 1998) or oncogenes (Dlugosz et al., 1995). Using the skin organ culture system, we have shown that the induction of HB-EGF and amphiregulin (AR) expression during wounding is strongly dependent on ErbB signaling (Stoll et al., 1997), and also on downstream signaling through the extracellular signal-regulated kinase (ERK) pathway (Stoll et al., 2002).
Cultured normal human keratinocytes (NHKs) display many features of reepithelializing skin, including high rates of proliferation, active migration, and the expression of keratins such as K6 and K16. Proliferation and migration of NHKs are strongly dependent on ErbB signaling (Cook et al., 1991b; Klein et al., 1992; McCawley et al., 1998). Conditioned medium (CM) produced by NHKs stimulates DNA synthesis in a way that can be partially blocked with antibodies against various ErbB ligands and strongly blocked by antibodies against ErbB1 (Coffey et al., 1987; Cook et al., 1991a; Pittelkow et al., 1993, 1994; Hashimoto et al., 1994; Shirakata et al., 2000). Moreover, we and others have observed that it is very difficult to obtain proliferative quiescence in NHKs by removal of growth factors (GFs) (Coffey et al., 1987; Klein et al., 1992; Praskova et al., 2002). Together, these findings are strongly suggestive of an autocrine mechanism of ErbB activation in NHKs. However, the exact ErbB species and downstream effectors being activated by this pathway, the ligands involved, and the mechanism(s) by which ligand(s) are made available for receptor stimulation remain incompletely defined.
Using the skin organ culture system, we have shown that broad-spectrum metalloproteinase (MP) inhibitors markedly reduce ERK phosphorylation (Stoll et al., 2002). These experiments suggest that the basal activity of ERK in human epidermis is controlled by release of preformed, membrane-associated ErbB ligand precursors, which are able to stimulate ErbB1 upon proteolytic release, leading to ERK activation. In this report, we further investigate the mechanisms responsible for the maintenance of autocrine ErbB signaling in NHKs. Our results demonstrate that AR released by one or more MPs acts exclusively over ErbB1 to maintain basal levels of ERK phosphorylation in GF-depleted NHK. Our findings illuminate a distinctive autocrine behavior of NHKs that is likely to be of importance in wound healing and hyperproliferative skin conditions.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
, AR, HB-EGF, epiregulin, and betacellulin were from R&D Systems (Minneapolis, MN). Recombinant human EGF (rhEGF) was from Preprotech (Rocky Hill, NJ). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG and protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA). PD158780, PD153035, AG825, GM6001, and MMP-2/MMP-9 inhibitor II [(2R)-[(4-biphenylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide] were from Calbiochem (San Diego, CA). Geldanamycin was a kind gift from Dr. William B. Pratt *Department of Pharmacology, University of Michigan Medical School).
Cell Culture and Stimulation of Keratinocytes
NHKs were obtained from sun-protected adult skin by trypsin flotation and propagated in modified MCDB 153 medium (complete M154; Cascade Biologics, Portland OR, containing EGF, insulin, hydrocortisone, and bovine pituitary extract) at a calcium concentration of 0.1 mM, as described previously (Stoll et al., 2001). NHKs were deprived of GFs for 24–48 h by maintenance in M154 containing 0.1 mM calcium but lacking growth supplements (basal M154 medium). For experiments involving inhibitors, the basal M154 was removed, the cells were washed twice with solution A (22.5 mM HEPES, 7.5 mM glucose, 2.25 mM KCl, 97.5 mM NaCl, 0.74 mM Na2HPO4 · 7H2O, pH 7.4), and the medium was replaced ("preincubated") with fresh basal M154 containing various inhibitors or DMSO vehicle. The cells were then returned to the incubator for 5–240 min. Ligands (or phosphate-buffered saline [PBS] as a control) were then added directly to the preincubation medium for 5–120 additional minutes; therefore, inhibitors were present throughout the period of exposure to ligand. After stimulation, lysates were harvested by scraping into lysis buffer (50 mM Tris, pH 7.5, 5 mM EGTA, 120 mM NaCl, 20 mM 
-glycerophosphate, 1% NP-40, 15 mM sodium pyrophosphate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 10 mM sodium orthovanadate, 50 mM sodium fluoride, 20% glycerol) with a rubber policeman. The lysate was clarified by centrifuging at 12,000 rpm for 15 min, and the supernatant was retained for further analysis. Protein concentrations were estimated using the Bio-Rad DC assay kit (Bio-Rad, Hercules, CA).
HaCaT cells (Boukamp et al., 1988) were obtained from Dr. Norbert Fusenig and propagated in DMEM as described previously (Stoll et al., 1998). HaCaT cells were rendered quiescent by 24 h of incubation in DMEM without serum, as described previously (Iordanov et al., 2002).
Western Blotting
Five to 20 µg of lysate protein was denatured by heating to 95°C for 5 min in 1x Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol), separated on 4–20% Tris-glycine gradient polyacrylamide gels (Invitrogen, Carlsbad, CA) and electrophoretically transferred onto polyvinylidene difluoride membranes (Invitrogen) according to the manufacturer's directions. Filters were washed with Dulbecco's PBS containing 0.1% Tween 20 (PBST), and then incubated in blocking buffer (0.1% Tween 20, 5% nonfat dry milk) with gentle rocking at room temperature for 30–60 min. Primary antibody incubations were performed in blocking buffer. Anti-ErbB1, anti-ErbB2, and anti-phospho-tyrosine were used at 1 µg/ml, and anti-ERK, anti-phospho-ERK, and anti-ErbB1 pY 1148 were used at a dilution of 1:1000. Primary antibody incubations were performed overnight at 4°C with gentle rocking. Subsequent to this, filters were rinsed three times for 10 min each at room temperature with PBST. After the third rinse, filters were incubated with the appropriate secondary antibody in blocking buffer for 1 h at room temperature, and then rinsed thrice for 10 min in PBST. Detection was performed using enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) as directed by the manufacturer.
Immunoprecipitation
Immunoprecipitation was performed essentially as described previously (Stoll et al., 2001). Briefly, 200 µg of cell lysate in 500 µl of lysis buffer was incubated with 500 ng of anti-ErbB1 (Ab-13), anti-ErbB2 (Ab-2), or with 500 ng of the appropriate isotype control antibody overnight at 4°C with rotation. Immune complexes were captured using protein A-agarose beads according to the manufacturer's instructions (Santa Cruz Biotechnology). Bound proteins were eluted by boiling in Laemmli sample buffer, and the supernatant was analyzed by Western blotting as described above.
Enzyme-linked Immunosorbent Assay (ELISA)
AR was quantitated in unconcentrated NHK supernatants using an ELISA (R&D Systems) with microtiter plates precoated with goat anti-mouse IgG, according to the manufacturer's instructions. rhAR was used as the standard. Samples with optical density values >2.0 were diluted 1:8. Results of duplicate determinations were averaged; between-determination variation was <20%.
Immunofluorescence
NHKs were grown to 40% confluence on sterile glass coverslips, and then were depleted of GFs for 2 d, followed by two washes in solution A and a 20-min preincubation in fresh basal M154 medium. After stimulation, the coverslips were rinsed twice in solution A, immediately fixed in freshly prepared 4% paraformaldehyde, and immunostained as described previously (Stoll et al., 2001). Ab14 (Labvision), a mixture of three mAb specific for the extracellular domain of ErbB1, was used at 0.4 µg/ml. Equivalent molar amounts of the isotype control antibodies MOPC 31c (IgG1) and UPC 10 (IgG2a) yielded negative staining (unpublished data). The secondary antibody was FITC-conjugated goat anti-mouse IgG. PBS containing 1% bovine serum albumin was used as the diluent. Slides were visualized using an Axioskop microscope equipped for fluorescence (Carl Zeiss, Jena, Germany). Digital images were obtained using a 2.2 megapixel diode array camera (Optronics, Goleta, CA).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
|
When 1 ng/ml EGF was used for stimulation of NHKs that had been depleted of GFs for 48 h, we observed a marked increase in EGF-stimulated ERK phosphorylation. This increase was reduced to below basal levels in the presence of 200 nM of the ErbB RTKI PD158780 (Figure 2A), which is highly selective for ErbB RTKs at this concentration (Rewcastle et al., 1998). Similar results were observed for PD153035, another pan-ErbB RTK inhibitor (Kansra et al., 2002; Stoll et al., 2002; and Kansra, Stoll., and Elder, unpublished data). However, as assessed using an antibody specific for ErbB1 pY 1148, a known ErbB1 autophosphorylation site (Margolis et al., 1989), there was little (Figure 2A) or no (Figure 2B) detectable increase in ErbB1 autophosphorylation in response to 1 ng/ml EGF. When the concentration of EGF was increased to 100 ng/ml, strong autophosphorylation of ErbB1 was observed (Figure 2B). Interestingly, despite these strong differences in ErbB1 autophosphorylation, the ERK phosphorylation responses to 1 ng/ml versus100 ng/ml EGF were very similar, being only slightly stronger and more prolonged in response to 100 ng/ml EGF (Figure 2B). To determine the lowest concentration of EGF that could stimulate ERK phosphorylation, we performed a more detailed dose-response curve. As shown in Figure 3, EGF concentrations as low as 0.2 ng/ml increased ERK phosphorylation above basal levels. In contrast, ErbB1 tyrosine phosphorylation was detectably increased only at 10 and 100 ng/ml EGF, as assessed either by antibodies against phosphotyrosine or ErbB1 pY 1148. From these data, we concluded ErbB RTK activity is required for maintaining basal levels of autocrine ERK phosphorylation in NHKs and that substantial ERK activation could be accomplished with minimal ErbB tyrosine phosphorylation.
|
|
Because neither PD158780 nor PD153035 is selective for ErbB1, and because NHKs express substantial quantities of ErbB2 (Stoll et al., 2001), we next wanted to specifically examine the possible contribution of ErbB2 to signaling from ErbB to ERK. As shown in Figure 4A, there was no evidence for tyrosine phosphorylation of ErbB2 under basal or EGF-stimulated conditions, as determined by immunoprecipitation and Western blotting. Pretreatment with geldanamycin, which causes proteolytic degradation of ErbB2 (Tikhomirov and Carpenter, 2000), did not inhibit either basal or EGF-stimulated 180-kDa tyrosine phosphorylation or phospho-ERK, despite causing near-complete loss of ErbB2 (Figure 4B), and near-complete inhibition of heregulin-stimulated tyrosine phosphorylation of ErbB2 in MD-MBA-453 cells (unpublished data). Finally, the ErbB2-selective tyrosine kinase inhibitor AG825 (Tsai et al., 1996) had no effect on basal or EGF-stimulated ERK phosphorylation (Figure 4C). Together, these results suggested that ErbB2 is not involved in the regulation of autocrine or EGF-stimulated ERK phosphorylation in NHKs.
|
Given that NHKs express only very low levels of ErbB3 and no detectable ErbB4 (Stoll et al., 2001), the foregoing results suggested that ErbB1 might be responsible for the observed basal levels of ERK phosphorylation. To more specifically demonstrate this, we used the ErbB1-neutralizing mAb 225 IgG (Gill et al., 1984). When NHKs were incubated with 225 IgG, basal ERK phosphorylation was abolished. This antibody also completely blocked ERK phosphorylation stimulated by 1 ng/ml EGF. However, it yielded progressively less inhibition as the EGF concentration was increased to 10 and 100 ng/ml (Figure 5). Noting that the 225 IgG antibody was present at only twofold molar excess >100 ng/ml EGF, it is likely that 225 IgG was unable to effectively compete with EGF for access to ErbB1 at high EGF concentrations. This resulted in ineffective inhibition of ERK phosphorylation, because we have shown that minor increases in ErbB1 tyrosine phosphorylation provoke large increases in ERK phosphorylation in this system (Figures 2, 3, and 5).
|
We next characterized the subcellular localization of ErB1 in response to autocrine stimulation as well as various concentrations of EGF by immunofluorescent staining of NHKs with a specific anti-ErbB1 antibody. As shown in Figure 6, under basal conditions (48 h of GF deprivation followed by 20-min preincubation in fresh medium), most of the ErbB1 is found in a "chicken-wire" pattern indicative of plasma membrane localization. When preincubation in fresh medium was omitted to observe the possible effect of autocrine ligands accumulating over the 48-h period of GF deprivation, substantial membrane localization of ErbB1 was still observed (unpublished data). Recalling that substantial ERK phosphorylation is observed under basal conditions (Figure 1B), these results indicate that ErbB1 is signaling to ERK largely at the plasma membrane in response to autocrine ErbB1 ligands. On stimulation with 0.1 ng/ml EGF, ErbB1 was still detected primarily in a plasma membrane pattern, but the apposing membranes of adjacent cells became separated from each other. The mechanism underlying this phenomenon remains to be elucidated. At 1 ng/ml EGF, the staining pattern once again resembled that observed under basal conditions. However, upon stimulation with larger amounts of EGF (10 and 100 ng/ml) membrane staining was lost, and staining became more punctate and located closer to the nucleus, indicative of receptor internalization. We also observed some ErbB1 staining in small, ill-defined patches (Figure 6A, arrowheads). Whereas the precise nature and subcellular localization of these patches remain to be defined, they could represent lipid rafts (Miljan and Bremer, 2002).
|
Because many receptor ligands, including ErbB ligands, are released from transmembrane precursors by MPs (Gschwind et al., 2001), we asked whether basal levels of ERK phosphorylation in NHKs could be reduced by the broad-spectrum MP inhibitors GM6001 (Holleran et al., 1997) and MMP-2/MMP-9 inhibitor II (Pikul et al., 1998; Tamura et al., 1998). As shown in Figure 7, A and B, basal ERK phosphorylation was markedly reduced by both compounds, and inhibition could be overcome by 1 ng/ml EGF. To demonstrate that release of membrane-bound GF is responsible for the basal activation state of ErbB1, we investigated the tyrosine phosphorylation status of ErbB1 by immunoprecipitation and Western blotting. As shown in Figure 7C, autocrine ErbB1 tyrosine phosphorylation was markedly reduced by GM6001 treatment, and inhibition could be overcome by 1 ng/ml EGF. To determine whether the observed effects of GM6001 were due to inhibition of MP-mediated release of soluble factors, we collected NHK-conditioned medium (NHK-CM) for 24 h in the presence or absence of GM6001, then used these CM to treat quiescent HaCaT cells followed by assessment of ERK phosphorylation (Figure 7D). HaCaT cells were used because they are keratinocyte-derived, but unlike NHKs, they have a low basal level of ERK phosphorylation at quiescence (Iordanov et al., 2002). As shown in Figure 7D, GM6001 treatment during the medium conditioning period markedly decreased the ability of NHK-CM to stimulate ERK phosphorylation in the HaCaT indicator cells. This decrease was not reproduced by addition of GM6001 to NHK-CM before addition to the HaCaT indicator cells, indicating that GM6001 is not acting directly on ErbB1 or between ErbB1 and ERK. Finally, ERK phosphorylation in response to NHK-CM was completely blocked by the ErbB RTK inhibitor PD158780. Together, these observations demonstrate that GM6001 causes a reduction in soluble ErbB ligand production by NHKs, resulting in lower levels of ErbB1 signaling to ERK.
|
In an effort to define the GF(s) that might be involved in this pattern of autocrine stimulation, we treated GF-deprived NHKs with a panel of neutralizing mAbs directed against various EGF-like growth factors. As shown in Figure 8A, a neutralizing mAb directed against AR abrogated basal ERK phosphorylation and reduced basal tyrosine phosphorylation of ErbB1, whereas a neutralizing antibody directed against HB-EGF was ineffective against both responses. Antibodies directed against TGF-, betacellulin, and epiregulin also were ineffective (unpublished data). Using an ELISA specific for AR, we measured AR levels in CM harvested from three independent experiments, one of which also is depicted in Figure 1B. As shown in Figure 8B, AR reappeared in the CM with a time course consistent with the reappearance of ERK phosphorylation (Figure 1B), becoming detectable over background levels at 120 min and reaching 
1 ng/ml by 240 min. AR continued to accumulate over a 24-h period, reaching a level of 5 ng/ml (Figure 8C). Elaboration of AR into the CM was markedly and significantly reduced by either GM6001 or MMP-2/MMP-9 inhibitor II, demonstrating a dependence upon MP activity (Figure 8C).
|
To determine whether EGF and AR exert similar effects on NHK signal transduction, we treated NHK with equimolar concentrations of rhEGF or rhAR, in the presence or absence of 225IgG. As shown in Figure 9, both rhEGF rhAR stimulated ErbB1 autophosphorylation and ERK phosphorylation. rhEGF was more potent and effective than rhAR in eliciting these responses (see Discussion). The effects of AR were completely blocked by 5 µg/ml 225 IgG, indicating that its effects were elicited by binding to and activation of ErbB1.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
; Iordanov et al., 2002; Kansra et al., 2002; Stoll et al., 2002). We became interested in this phenomenon while trying to understand the variable levels of ERK phosphorylation we observed under basal conditions (Figure 1A). Additional experiments revealed a biphasic change in levels of ERK phosphorylation and ErbB1 tyrosine phosphorylation as a function of preincubation time, with a rapid and marked decline >10–15 min of preincubation followed by recovery to near-original levels at 120–240 min (Figure 1B). These experiments also revealed a decrease in ERK phosphorylation at 48 h of GF deprivation compared with 24 h, which may be attributable to the approach of confluence (Figure 1B, bottom).
Subsequent experiments demonstrated that this "basal" level of ERK phosphorylation was due to MP-mediated release of one or more soluble ErbB ligands (Figure 7). To determine which ErbB ligand(s) might be responsible for this behavior, we treated GF-depleted NHKs with neutralizing antibodies against various ErbB ligands. Basal levels of ERK phosphorylation could be blocked by pretreatment with neutralizing antibodies against AR, but not against HB-EGF (Figure 8A). Antibodies against TGF-, betacellulin, and epiregulin also were ineffective (unpublished data). Moreover, the time course of accumulation of soluble AR in NHK-CM (Figure 8B) correlated with the reappearance of ERK phosphorylation after medium change (Figure 1B). Together, these results demonstrated that the predominant ErbB ligand responsible for autocrine ERK activation in NHK is AR.
Both the autocrine ERK activation response (Figure 7) and AR elaboration into the culture medium (Figure 8C) could be blocked by either GM6001 or MMP-2/MMP-9 inhibitor II, demonstrating that AR release is dependent upon MP activity. Other than this, the nature of the proteolytic activity responsible for cleavage of AR in NHKs is currently unknown. Ullrich and colleagues have identified an AR-driven ErbB1 activation circuit in oral squamous cell carcinoma cells, in which ADAM17 (a disintegrin and a metalloproteinase-17), also known as TACE, was identified as a major source of pro-AR proteolytic activity (Gschwind et al., 2003). Also, ADAM-10 has been implicated as a major source of pro-HB-EGF proteolytic activity in cardiac hypertrophy (Lemjabbar and Basbaum, 2002).
Our laboratory is currently investigating the nature of the MP(s) responsible for regulating AR release in NHKs. Our studies are being guided by available knowledge of MP expression in NHKs and skin. The MPs can be subdivided into the matrix metalloproteinases (MMPs) and the ADAMs. Although many MMPs are released into the extracellular space, they are still candidates for AR cleavage because certain MMPs (including tolloid, tolloid-like-1, MMP-2, and MMP-9) are known to bind to the surface of keratinocytes (Sternlicht and Werb, 2001; Franzke et al., 2002; Rattenholl et al., 2002; Veitch et al., 2003), and MT1-MMP (MMP-14) is membrane anchored. In resting adult skin, most MMPs are not constitutively expressed in keratinocytes, with the exception of MMP-7 (matrilysin) in eccrine sweat gland epithelium, MMP-2 (gelatinase A) in occasional basal keratin-ocytes, MMP-19, tolloid, and tolloid-like 1. However, several MMPs are induced or up-regulated in keratinocytes in the context of inflammation, embryogenesis, and tissue repair/remodeling, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-10, and MMP-19 (Kahari and Saarialho-Kere, 1997; Rattenholl et al., 2002; Impola et al., 2003; Kerkela and Saarialho-Kere, 2003; Sadowski et al., 2003; Veitch et al., 2003). Unstimulated NHKs in culture produce modest amounts of MMP-1, MMP-2, and MMP-9, but little MMP-10 or MMP19 (Varani et al., 1995a; Kahari and Saarialho-Kere, 1997; Impola et al., 2003; Kerkela and Saarialho-Kere, 2003; Sadowski et al., 2003). In contrast, NHKs produce substantial amounts of tolloid and tolloid-like 1 MPs (Rattenholl et al., 2002; Veitch et al., 2003). Compared with the MMPs, fewer studies have addressed the expression of the various ADAMs in NHKs. However, ADAM-9, ADAM-10, and ADAM-17 have been detected in NHKs and skin by immunocytochemical techniques, as well as by reverse transcription-polymerase chain reaction (Franzke et al., 2002; Kawaguchi et al., 2004). We have been able to detect low levels of ADAM-10 and ADAM-17 in NHK by Western blotting (unpublished data).
We also were interested in identifying the membrane receptor(s) through which the autocrine AR signal is passed to ERK. We have previously shown that NHKs express large amounts of ErbB1 and ErbB2, but very little ErbB3 and no detectable ErbB4 (Stoll et al., 2001). Because the kinase activity of ErbB3 is severely impaired (Guy et al., 1994), the most likely carriers of the ErbB signal are ErbB1 and ErbB2. Basal ERK phosphorylation was greatly reduced by pretreatment with two different ErbB-specific RTKIs: PD158780 (Figure 2A) and PD153035 (Kansra et al., 2002; Stoll et al., 2002) (unpublished data), demonstrating the dependence of basal ERK phosphorylation upon ErbB activation. However, neither of these agents are specific for ErbB1 (Rewcastle et al., 1998; Stoll et al., 2001). AR and EGF are known to activate ErbB1-ErbB2 heterodimers even more effectively than they activate ErbB1 homodimers (Klapper et al., 2000; Olayioye et al., 2000). However, tyrosine phosphorylation of ErbB2 was undetectable under basal or EGF-stimulated conditions (Figure 4A). This result is strongly suggestive of a lack of ErbB1-ErbB2 heterodimer formation and is consistent with our previous observation that ErbB1 and ErbB2 are segregated to different subcellular compartments in NHKs, with ErbB1 on the cell surface and ErbB2 on intracellular vesicles (Stoll et al., 2001). To explore the possible involvement of ErbB2 as homodimers or in conjunction with ErbB3, we treated NHKs with geldanamycin or AG825. Geldanamycin selectively increases the degradation of ErbB2 by caspase-dependent cleavage at ErbB2-specific residues within the kinase domain (Tikhomirov and Carpenter, 2001, 2003). AG825 is an RTKI that is selective for ErbB2 in vitro (Osherov et al., 1993). As shown in Figure 4, B and C, neither agent reduced basal or EGF-stimulated ERK phosphorylation. Although it remains possible that some residual ErbB2 RTK activity remained under our experimental conditions, when taken together the results shown in Figure 4 strongly suggest that neither ErbB2 homodimers nor ErbB2-ErbB3 heterodimers plays a significant role in maintaining basal ERK phosphorylation in NHKs. Corroborating the above-mentioned results, Figures 5 and 9 demonstrate that basal ERK phosphorylation was markedly diminished in the presence of the ErbB1-specific neutralizing antibody 225 IgG (Gill et al., 1984).
Having identified ErbB1 as the sole player in the AR-driven autocrine circuit driving ERK activation in NHKs, we also were interested in defining its subcellular distribution under conditions of autocrine stimulation. Immunofluorescence experiments revealed that the bulk of ErbB1 was located at the plasma membrane under conditions of GF deprivation and in the presence of low levels (
1 ng/ml) of EGF (Figure 6). Receptor internalization was markedly increased at 10 and 100 ng/ml EGF, in concert with increased ErbB1 tyrosine phosphorylation (Figures 2, 3, 5, and 9).
ErbB1 tyrosine phosphorylation is known to create docking sites for c-Cbl, which is directly involved in internalization and ubiquitin-dependent lysosomal degradation of ErbB1 (Levkowitz et al., 1999; Thien and Langdon, 2001; Soubeyran et al., 2002). The very limited phosphorylation and internalization of ErbB1 at EGF concentrations 1 ng/ml suggest that c-Cbl is not engaged with ErbB1 after treatment with low concentrations of EGF, due to insufficient tyrosine phosphorylation of ErbB1. We would speculate that one or more tyrosine phosphatases may rapidly dephosphorylate ErbB1 after it is stimulated with autocrine AR or with low concentrations of EGF, but not before ErbB1 has established a signaling connection with ERK. This could explain the substantial signaling from ErbB1 to ERK that takes place in the relative absence of detectable ErbB1 tyrosine phosphorylation or internalization.
We found that the concentration of AR in NHK-CM is 5 ng/ml after 24 h of GF deprivation (Figure 8C), which translates into 2.5 ng/ml EGF. Assuming approximately equal biological potency of native AR and recombinant EGF (Cook et al., 1991a), this concentration of AR would be consistent with the limited internalization of ErbB1 that we observed under autocrine conditions (Figure 6), and with the pronounced autocrine phosphorylation of ERK demonstrated in Figure 1B. Curiously, however, the amount of AR produced by NHKs (1 ng/ml after 4 h and 5 ng/ml after 24 h; Figure 8) was less than the amount of purified rhAR needed to stimulate these responses when added to NHKs (1.7 nM 
18.7 ng/ml; Figure 9). According to data provided by the manufacturers, the rhAR preparation we used (which is synthesized in Escherichia coli) is substantially less potent than rhEGF. Thus, the ED for stimulation of proliferation in Balb/3T3 cells was 5–15 50ng/ml for rhAR, compared with <0.1 ng/ml for EGF. In contrast, Cook et al. (1991a) have shown that native AR purified from NHKs is as potent or even more potent as a mitogen than EGF, when tested on mouse keratinocytes. We show in Figure 8B that the amount of AR that accumulates in NHK-CM after 2 h of GF deprivation (0.4 ng/ml) is adequate to stimulate ERK phosphorylation (Figure 1B) to an extent similar to 0.5 ng/ml rhEGF (Figure 3). Thus, in our hands, NHK-derived AR seems to be comparable with rhEGF in potency. AR is naturally secreted as a prepropeptide of 252 amino acids, and >100 of the N-terminal-most residues are not present in rhAR. Moreover, natural AR is subjected to extensive posttranslational glycosylation (Piepkorn et al., 1998) that is not possible in E. coli. Based on these findings, we suspect that native AR produced by NHKs is substantially more potent than rhAR, due to the presence of additional N-terminal amino acids and/or appropriate posttranslational modifications.
In aggregate, our findings indicate that AR is the major ligand responsible for autocrine ERK activation in NHKs and are consistent with previous reports that AR is a major autocrine mitogen in this system (Cook et al., 1991a; Piepkorn et al., 1994). Our results also demonstrate that one or more MPs are responsible for generation of soluble AR in NHKs. We believe that this autocrine, AR-driven ERK activation circuit is likely to be involved in the control of human keratinocyte proliferation in vivo, as suggested by the hyperplastic phenotype of mice engineered to overexpress AR in basal layer of the skin (Cook et al., 1997). Indeed, our findings could help explain a long-puzzling feature of psoriasis: it has not been possible to demonstrate increased levels of ErbB1 tyrosine phosphorylation in lesional psoriatic skin (Krane et al., 1992) despite reports of robust Ras activation (Lin et al., 1999) and ERK phosphorylation (Haase et al., 2001). Our findings also may have important implications for ErbB-directed cancer therapy, because it may be important to completely block ErbB autophosphorylation to shut off signaling via the ERK pathway. Clearly, an improved understanding of the expression of autocrine ErbB ligands and the context-dependent proteolytic milieu responsible for release of AR and other ErbB ligands in skin will be of major importance to cutaneous biologists in the coming years.
|
ACKNOWLEDGMENTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
|
Footnotes |
|---|
These authors made equal contributions to this study. 
Present address: Department of Cell Biology, Neurobiology and Anatomy, University of Cincinnati, 3125 Eden Ave., Cincinnati, OH 45267-0521.
Corresponding authors. E-mail addresses: jelder{at}umich.edu; sanjay.kansra{at}uc.edu.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONACKNOWLEDGMENTSREFERENCES |
|---|
Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A., and Fusenig, N.E. ((1988). ). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106, , 761–771.
Brown, G.L., Nanney, L.B., Griffen, J., Cramer, A.B., Yancey, J.M., Curtsinger, L.D., Holtzin, L., Schultz, G.S., Jurkiewicz, M.J., and Lynch, J.B. ((1989). ). Enhancement of wound healing by topical treatment with epidermal growth factor. N. Engl. J. Med. 321, , 76–79.[Abstract]
Cai, T., Nishida, K., Hirano, T., and Khavari, P.A. ((2002). ). Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J. Cell Biol. 159, , 103–112.
Coffey, R.J., Jr., Derynck, R., Wilcox, J.N., Bringman, T.S., Goustin, A.S., Moses, H.L., and Pittelkow, M.R. ((1987). ). Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature 328, , 817–820.[CrossRef][Medline]
Cook, P.W., Mattox, P.A., Keeble, W.W., Pittelkow, M.R., Plowman, G.D., Shoyab, M., Adelman, J.P., and Shipley, G.D. ((1991a). ). A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol. Cell. Biol. 11, , 2547–2557.
Cook, P.W., Piepkorn, M., Clegg, C.H., Plowman, G.D., DeMay, J.M., Brown, J.R., and Pittelkow, M.R. ((1997). ). Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Investig. 100, , 2286–2294.[Medline]
Cook, P.W., Pittelkow, M.R., Keeble, W.W., Graves-Deal, R., Coffey, R., Jr., and Shipley, G.D. ((1992). ). Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. 52, , 3224–3227.
Cook, P.W., Pittelkow, M.R., and Shipley, G.D. ((1991b). ). Growth factor-independent proliferation of normal human neonatal keratinocytes: production of autocrine- and paracrine-acting mitogenic factors. J. Cell. Physiol. 146, , 277–289.[CrossRef][Medline]
Cribbs, R.K., Luquette, M.H., and Besner, G.E. ((1998). ). Acceleration of partial-thickness burn wound healing with topical application of heparin-binding EGF-like growth factor (HB-EGF). J. Burn Care Rehabil. 19, , 95–101.[CrossRef][Medline]
De Potter, I.Y., Poumay, Y., Squillace, K.A., and Pittelkow, M.R. ((2001). ). Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp. Cell Res. 271, , 315–328.[CrossRef][Medline]
Dlugosz, A.A., Cheng, C., Williams, E.K., Darwiche, N., Dempsey, P.J., Mann, B., Dunn, A.R., Coffey, R.J., Jr., and Yuspa, S.H. ((1995). ). Autocrine transforming growth factor alpha is dispensible for v-rasHa-induced epidermal neoplasia: potential involvement of alternate epidermal growth factor receptor ligands. Cancer Res. 55, , 1883–1893.
Downing, M.T., Brigstock, D.R., Luquette, M.H., Crissman-Combs, M., and Besner, G.E. ((1997). ). Immunohistochemical localization of heparin-binding epidermal growth factor-like growth factor in normal skin and skin cancers. Histochem. J. 29, , 735–744.[CrossRef][Medline]
Draper, B.K., Komurasaki, T., Davidson, M.K., and Nanney, L.B. ((2003). ). Epiregulin is more potent than EGF or TGF-alpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation. J. Cell Biochem. 89, , 1126–1137.[CrossRef][Medline]
Elder, J.T., Fisher, G.J., Lindquist, P.B., Bennett, G.L., Pittelkow, M.R., Coffey, R., Jr., Ellingsworth, L., Derynck, R., and Voorhees, J.J. ((1989). ). Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243, , 811–814.
Franzke, C.W., et al. ((2002). ). Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 21, , 5026–5035.[CrossRef][Medline]
Gill, G.N., Kawamoto, T., Cochet, C., Le, A., Sato, J.D., Masui, H., McLeod, C., and Mendelsohn, J. ((1984). ). Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259, , 7755–7760.
Grotendorst, G.R., Soma, Y., Takehara, K., and Charette, M. ((1989). ). EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J. Cell. Physiol. 139, , 617–623.[CrossRef][Medline]
Gschwind, A., Hart, S., Fischer, O.M., and Ullrich, A. ((2003). ). TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 22, , 2411–2421.[CrossRef][Medline]
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., and Ullrich, A. ((2001). ). Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20, , 1594–1600.[CrossRef][Medline]
Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L. ((1994). ). Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91, , 8132–8136.
Haase, I., Hobbs, R.M., Romero, M.R., Broad, S., and Watt, F.M. ((2001). ). A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J. Clin. Investig. 108, , 527–536.[CrossRef][Medline]
Hackel, P.O., Zwick, E., Prenzel, N., and Ullrich, A. ((1999). ). Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11, , 184–189.[CrossRef][Medline]
Hashimoto, K., Higashiyama, S., Asada, H., Hashimura, E., Kobayashi, T., Sudo, K., Nakagawa, T., Damm, D., Yoshikawa, K., and Taniguchi, N. ((1994). ). Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J. Biol. Chem. 269, , 20060–20066.
Hebda, P.A. ((1988). ). Stimulatory effects of transforming growth factor-beta and epidermal growth factor on epidermal cell outgrowth from porcine skin explant cultures. J. Investig. Dermatol. 91, , 440–445.[CrossRef][Medline]
Holleran, W.M., Galardy, R.E., Gao, W.N., Levy, D., Tang, P.C., and Elias, P.M. ((1997). ). Matrix metalloproteinase inhibitors reduce phorbol ester-induced cutaneous inflammation and hyperplasia. Arch. Dermatol. Res. 289, , 138–144.[CrossRef][Medline]
Hubbard, S.R., Mohammadi, M., and Schlessinger, J. ((1998). ). Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273, , 11987–11990.
Impola, U., Toriseva, M., Suomela, S., Jeskanen, L., Hieta, N., Jahkola, T., Grenman, R., Kahari, V.M., and Saarialho-Kere, U. ((2003). ). Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int. J. Cancer 103, , 709–716.[CrossRef][Medline]
Iordanov, M.S., Choi, R.J., Ryabinina, O.P., Dinh, T.H., Bright, R.K., and Magun, B.E. ((2002). ). The UV (Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor. Mol. Cell. Biol. 22, , 5380–5394.
Kahari, V.M., and Saarialho-Kere, U. ((1997). ). Matrix metalloproteinases in skin. Exp. Dermatol. 6, , 199–213.[CrossRef][Medline]
Kansra, S., Stoll, S.W., and Elder, J.T. ((2002). ). Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation. Biochem. Biophys. Res. Commun. 295, , 1108–1117.[CrossRef][Medline]
Kawaguchi, M., Mitsuhashi, Y., and Kondo, S. ((2004). ). Localization of tumour necrosis factor-alpha converting enzyme in normal human skin. Clin. Exp. Dermatol. 29, , 185–187.[CrossRef][Medline]
Kerkela, E., and Saarialho-Kere, U. ((2003). ). Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol. 12, , 109–125.[CrossRef][Medline]
Kiguchi, K., Beltran, L., Rupp, T., and DiGiovanni, J. ((1998). ). Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol. Mol. Carcinog. 22, , 73–83.[CrossRef][Medline]
Klapper, L.N., Kirschbaum, M.H., Sela, M., and Yarden, Y. ((2000). ). Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, , 25–79.[Medline]
Klein, S.B., Fisher, G.J., Jensen, T.C., Mendelsohn, J., Voorhees, J.J., and Elder, J.T. ((1992). ). Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways. J. Cell. Physiol. 151, , 326–336.[CrossRef][Medline]
Krane, J.F., Gottlieb, A.B., Carter, D.M., and Krueger, J.G. ((1992). ). The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J. Exp. Med. 175, , 1081–1090.
Lemjabbar, H., and Basbaum, C. ((2002). ). Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 8, , 41–46.
